NEW YORK (GenomeWeb News) - Exact Sciences said on Monday that its board of directors has rejected a bid from Sequenom to buy the company for $1.50 per share in Sequenom common stock.

Exact said that the board agreed unanimously to rebuff Sequenom's proposed acquisition, and that the company is "actively pursuing a strategic alternative" that could offer greater value for shareholders than the Sequenom offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.